YYYue-Jin Yang

Yue-Jin Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yue-Jin Yang has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Wang

    6 shared publications
  • Qian Zhang

    5 shared publications
  • Jian-Jun Li

    Fuwai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College

    4 shared publications
  • Run-Lin Gao

    Coronary Heart Disease Center, Department of Cardiology, Fuwai Hospital and Cardiovascular Institute, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    4 shared publications
  • Yongjian Wu

    Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China

    4 shared publications
  • Bo Xu

    Department of Cardiology, Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    3 shared publications

Latest Publications

    • 1 July 2013
      • Vol. 41  (7) , 622-5

    [Crucial role of RhoA/ROCK pathway on modulating microenvironment after acute myocardial infarction].

    by Qian Zhang, Yue-Jin Yang, Hong Wang

  • Open Access

    Atorvastatin Enhance Efficacy of Mesenchymal Stem Cells Treatment for Swine Myocardial Infarction via Activation of Nitric Oxide Synthase

    by Lei Song, Yue-Jin Yang, Qiu-Ting Dong, Hai-Yan Qian, Run-Lin Gao, Shu-Bin Qiao, Rui Shen, Zuo-Xiang He, Min-Jie Lu, Shi-Hua Zhao, et al.

    In a swine model of acute myocardial infarction (AMI), Statins can enhance the therapeutic efficacy of mesenchymal stem cell (MSCs) transplantation. However, the mechanisms remain unclear. This study aims at assessing whether atorvastatin (Ator) facilitates the effects of MSCs through activation of nitric oxide synthase (NOS), especially endothelial nitric oxide synthase (eNOS), which is known to protect against ischemic injury. 42 miniswines were randomized into six groups (n = 7/group): Sham operation; AMI control; Ator only; MSC only, Ator+MSCs and Ator+MSCs+NG-nitrol-L-arginine (L-NNA), an inhibitor of NOS. In an open-heart surgery, swine coronary artery ligation and reperfusion model were established, and autologous bone-marrow MSCs were injected intramyocardium. Four weeks after transplantation, compared with the control group, Ator+MSCs animals exhibited decreased defect areas of both “perfusion” defined by Single-Photon Emission Computed Tomography (−6.2±1.8% vs. 2.0±5.1%, P = 0.0001) and “metabolism” defined by Positron Emission Tomography (−3.00±1.41% vs. 4.20±4.09%, P = 0.0004); Ejection fraction by Magnetic Resonance Imaging increased substantially (14.22±12.8% vs. 1.64±2.64%, P = 0.019). In addition, indices of inflammation, fibrosis, and apoptosis were reduced and survivals of MSCs or MSC-derived cells were increased in Ator+MSCs animals. In Ator or MSCs alone group, perfusion, metabolism, inflammation, fibrosis or apoptosis were reduced but there were no benefits in terms of heart function and cell survival. Furthermore, the above benefits of Ator+MSCs treatment could be partially blocked by L-NNA. Atorvastatin facilitates survival of implanted MSCs, improves function and morphology of infarcted hearts, mediated by activation of eNOS and alleviated by NOS inhibitor. The data reveal the cellular and molecular mechanism for anti-AMI therapy with a combination of statin and stem cells.


  • The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives

    by Xi-Mei Wang, Yue-Jin Yang, Yong-Jian Wu

    Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of oral anti-hyperglycemic agents that prolong the bioavailability of the endogenously secreted incretin hormone glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP), are effective in the treatment of diabetes. Accumulating data have indicated that DPP-4 inhibitors play important protective roles in the cardiovascular system. DPP-4 inhibitors act to decrease myocardial infarct size, stabilize the cardiac electrophysiological state during myocardial ischemia, reduce ischemia/reperfusion injury, and prevent left ventricular remodeling after myocardial infarction. Moreover, DPP-4 inhibitors can mobilize stem/progenitor cells to move to sites of cardiovascular injury, thus further promoting tissue repair. In addition, DPP-4 inhibitors not only improve myocardial metabolism but also regulate cardioactive peptides. DPP-4 inhibitors can also protect the vasculature through their anti-inflammatory and anti-atherosclerotic effects and through the ability of the inhibitors to promote vascular relaxation. Finally, the potential effects of DPP-4 inhibitors on blood pressure and lipid metabolism have also been investigated. However, some reports on the cardioprotective activities of DPP-4 inhibitors are controversial. Herein, we summarize the available data on cardiovascular protection by DPP-4 inhibitors that have emerged in recent years and discuss current position and future perspectives concerning the use of DPP-4 inhibitors in cardiovascular medicine.


  • Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis

    by Xiang-Dong Li, Yue-Jin Yang, Yong-Chen Hao, Ying Yang, Jing-Lin Zhao, Ke-Fei Dou, Dong-Feng Gu

    Background: Successful revascularization of coronary artery disease, especially ST-elevation myocardial infarction (STEMI), does not always mean optimal myocardial reperfusion in a portion of patients because of no-reflow phenomenon. We hypothesized that statins might attenuate the incidence of myocardial no-reflow when used before percutaneous coronary intervention (PCI). The purpose of this study was to summarize the evidence of pre-procedural statin therapy to reduce myocardial no-reflow after PCI. Methods: We searched the MEDLINE, Cochrane, and clinicaltrials.gov databases from inception to October 2012 for clinical trials that examined statin therapy before PCI. We required that studies initiated statins before PCI and reported myocardial no-reflow. A DerSimonian-Laird model was used to construct random-effects summary risk ratios. Results: In all, 7 studies with 3086 patients met our selection criteria. The use of pre-procedural statins significantly reduced post-procedural no-reflow by 4.2% in all PCI patients (risk ratio (RR) 0.56, 95% confidence interval (CI) 0.35 to 0.90, P=0.016), and attenuated by 5.0% in non-STEMI patients (RR 0.41, 95% CI 0.18 to 0.94, P=0.035). This benefit was mainly observed in the early or acute intensive statin therapy populations (RR 0.43, 95% CI 0.26 to 0.71, P=0.001). Conclusions: Acute intensive statin therapy before PCI significantly reduces the hazard of post-procedural no-reflow phenomenon. The routine use of statins before PCI should be considered.


  • Protein kinase A-mediated cardioprotection of Tongxinluo relates to the inhibition of myocardial inflammation, apoptosis, and edema in reperfused swine hearts

    by Xiang-Dong Li, Yue-Jin Yang, Yu-Tong Cheng, Ke-Fei Dou, Yi Tian, Xian-Min Meng

    Background: Our previous studies have demonstrated that Tongxinluo (TXL), a traditional Chinese medicine, can protect hearts against no-reflow and reperfusion injury in a protein kinase A (PKA)-dependent manner. The present study was to investigate whether the PKA-mediated cardioprotection of TXL against no-reflow and reperfusion injury relates to the inhibition of myocardial inflammation, edema, and apoptosis. Methods: In a 90-minute ischemia and 3-hour reperfusion model, minipigs were randomly assigned to sham, control, TXL (0.05 g/kg, gavaged one hour prior to ischemia), and TXL + H-89 (a PKA inhibitor, intravenously and continuously infused at 1.0 μg/kg per minute) groups. Myocardial no-reflow, necrosis, edema, and apoptosis were determined by pathological and histological studies. Myocardial activity of PKA and myeloperoxidase was measured by colorimetric method. The expression of PKA, phosphorylated cAMP response element-binding protein (p-CREB) (Ser133), tumor necrosis factor α (TNF-α), P-selectin, apoptotic proteins, and aquaporins was detected by Western blotting analysis. Results: TXL decreased the no-reflow area by 37.4% and reduced the infarct size by 27.0% (P133 p-CREB in the reflow and no-reflow myocardium (P <0.05). TXL inhibited the ischemia-reperfusion-induced elevation of myeloperoxidase activities and the expression of TNF-α and P-selectin, reduced myocardial edema in the left ventricle and the reflow and no-reflow areas and the expression of aquaporin-4, -8, and -9, and decreased myocytes apoptosis by regulation of apoptotic protein expression in the reflow and no-reflow myocardium. However, addition of the PKA inhibitor H-89 counteracted these beneficial effects of TXL. Conclusion: PKA-mediated cardioprotection of TXL against no-reflow and reperfusion injury relates to the inhibition of myocardial inflammation, edema, and apoptosis in the reflow and no-reflow myocardium.


  • Cardiac progenitor/stem cells on myocardial infarction or ischemic heart disease: what we have known from current research

    by Hao Zhang, Hong Wang, Na Li, Chang-En Duan, Yue-Jin Yang

    Stem cell therapy has become a promising method for many diseases, including ischemic heart disease and heart failure. Several kinds of stem cells have been studied for heart diseases. Of them, bone marrow stem cells (BMSCs), which have been used in many clinical trials, are the most understood one. But the effect of BMSCs is mediated by paracrine factors instead of direct turning into cardiomyocytes. On the other hand, a lot of evidences have shown that resident cardiac stem cells could turn into cardiomyocytes directly in vivo. Currently, seven kinds of resident cardiac stem cells have been discovered. However, their mechanisms, development origins, and relationships have yet to be fully understood. Moreover, two Phase I clinical trials have been performed recently. They show promising results. In this review, we will summarize the current research on these cardiac stem cells and the methods to enhance their effects in clinical applications.


  • Statin Administration Does Not Improve the Mobilization of Very Small Embryonic-Like Stem Cells (VSELs) in Contrast to Resveratrol Treatment in a Murine Model of Acute Myocardial Infarction

    by H. Wang, Y.-J. Yang, H.-Y. Qian, Q. Zhang, L.-J. Gao, P. Li, T.-J. Wang, S.-D. Wang

    We have found that short-term statin treatment plus stem cell transplantation in acutely infarcted hearts improves cardiac function because statins promote the efficacy of cellular cardiomyoplasty. Autologous Sca-1+Lin-CD45-(CXCR+) very small embryonic-like stem cell (VSEL) mobilization in acute myocardial infarction (AMI) correlates with the preservation of cardiac function. Whether short-term atorvastatin (Ator) can enhance the mobilization or recruitment of VSELs in AMI is still unclear. We divided mice into 4 groups: 1) sham; 2) AMI; 3) AMI+resveratrol (RSV) as a positive control; and 4) AMI+Ator. There was an increase in the circulating VSEL/full population of leukocytes (FPL) ratio 48 hours after AMI, and AMI+RSV increased it further. Ator administration did not increase the VSEL/FPL ratio. The cardiac stromal cell-derived factor-1 (SDF-1) and SDF-1α levels were in agreement with the results of VSEL mobilization. One week after AMI, more Sca-1+CXCR+ cells were recruited to the myocardium of AMI+RSV mice but not AMI+Ator mice. Short-term Ator administration failed to upregulate cardiac SDF-1 and could not enhance the recruitment of VSELs early after AMI.


  • The cardioprotection of simvastatin in reperfused swine hearts relates to the inhibition of myocardial edema by modulating aquaporins via the PKA pathway

    by Xiang-Dong Li, Yue-Jin Yang, Yong-Jian Geng, Yu-Tong Cheng, Hai-Tao Zhang, Jing-Lin Zhao, Jin-Qin Yuan, Run-Lin Gao


  • Comparison Between Radial and Femoral Approach for Percutaneous Coronary Intervention in Patients Aged 80 Years or Older

    by Fenghuan Hu, Yuejin Yang, Shubin Qiao, Bo Xu, Haibo Liu, Yongjian Wu, Jue Chen, Shijie You, Jilin Chen, Runlin Gao

    To compare safety and efficacy between the radial and femoral approach for percutaneous coronary intervention (PCI) in patients aged 80 years and older. Two hundred sixty-eight elderly patients (80-97 years old, 176 men) who underwent elective PCI between May 2003 and May 2007 were included in this study: the femoral (hereinafter referred to as the Femoral Approach Group) approach was used on 156 patients and radial (Radial Approach Group) on 112 patients. Clinical and procedural characteristics and the incidence of in-hospital major adverse cardiac events (MACE, including cardiac death, nonfatal myocardial infarction, and target lesion revascularization) were compared between the 2 groups. Procedural success rate was similar and >95% for both approaches. The radial approach was associated with longer cannulation (3.0 ± 2.8 minutes vs. 2.0 ± 1.9 minutes, P < 0.001), fluoroscopy time (23 ± 15 minutes vs. 19 ± 12 minutes, P = 0.03) and higher rate of crossover to an alternative access site (9.8% vs. 3.8%, P = 0.02) compared with the femoral approach, while ambulation time (5 ± 2 hours vs. 20 ± 4 hours, P < 0.001), and rates of access site bleeding (2.7% vs. 9.6%, P = 0.004), hematoma (4.5% vs. 10.9%, P = 0.006), or any vascular complication (7.1% vs. 23.7%, P < 0.001) were significantly reduced with the radial approach as opposed to femoral. Multivariate regression identifies the radial approach (OR = 0.25, CI = 0.09-0.75) as an independent negative predictor of postprocedural vascular complications. When compared to the femoral approach, PCI with the radial approach significantly reduces rates of vascular complications in high-risk populations of patients aged 80 years and older. However, efficacy and procedural success rates were similar for both groups whereas cannulation and fluoroscopy time longer and puncture failure rate higher with the radial approach than femoral.